Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 4, 2010, Pages 259-269

  Park, J Y ^a   Kim, K A ^a   Ryu, J H ^b   Lee, G H ^b   Jeon, S H ^b   Kim, J S ^b  

^a Korea University College of Medicine   (South Korea)

^b Hanlim Pharmaceutical Company Ltd   (South Korea)

Author keywords

Clopidogrel; Platelet aggregation; Salt substitution; SR26334

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; CLOPIDOGREL; LORACLE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDUCED HEADACHE; FATIGUE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; URTICARIA;

EID: 77950993856     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48259     Document Type: Article

References (42)

1. US Food and Drug Administration Web site. Approved drug products with therapeutic equivalence evaluations. Available at: http://lwww.fda.gov/cder/ob/ docs/preface/ecpreface.htm. Accessed March 31, 2009.
2. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects (WMAWeb site). Ferney-Vottaire, France: WMA. 1989; Available at: http://www.wma.net. Accessed March 31, 2009.
3. Food and Drug Administration. Guidance: Statistical procedure for bioequivalence studies using standard 2-treatment cross-over design: Statement under 21 CFR 10.9. Rockville, Md: US Dept of Health and Human Services. 1992.
4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
5. Food and Drug Administration of Korea (KFDA). Korea FDA guidelines for bioequivalence test. (KFDA Web site). Seoul, Korea: KFDA. 1996; Available at: http://www. kfda.go.kr. Accessed March 31, 2009.
6. Committee for Proprietary Medicinal Products (CPMP).Working Party on the Efficacy of Medicinal Products. Note for guidance: Investigation of bioavailability and bioequivalence (European Medicines Agency (EMEA) Web site). London, UK:EMEA. 2001; Available at: http://www.emea.eu.int. Accessed March 31, 2009.
7. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation- World Health Organization. Guideline for Good Clinical Practice (EMEA Web site). ICH Topic E6. Geneva, Switzerland: WHO. 2002; Available at: http://www.emea.eu.int. Accessed March 31, 2009.
8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005; 115: 101-108. (Pubitemid 39572762)
9. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999; 25 (Suppl): 25-28.
10. Charles SA. Supergenerics: a better alternative fro bilogenerics. Drug Discovery Today. 2005; 10: 533-535.
11. Chow SC, Liu J-P. Design and Analysis of Bioavailability and Bioequivalence Studies. New York, NY: Marcel Dekker Inc; 1992: 48-69.
12. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003; 31: 53-59. (Pubitemid 36735258)
13. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001; 45: 382-392. (Pubitemid 32105271)
14. Filipe A, Almeida S, Franco Spinola AC, et al. Single- dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 2009; 47: 187-194.
15. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double- blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51: 256-260.
16. Herbert JM, Frehel D, Vallee E, et al. Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Cardiovas Drug Rev. 1993; 11: 180.
17. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. J Lab Clin Med. 1941; 26: 1812-1822.
18. Jakubowski JA, Payne CD, Brandt JT et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006; 47: 377-384.
19. Jakubowski JA, Matsushima N, Asai F et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007; 63: 421-430. (Pubitemid 46426638)
20. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180: 713-718.
21. Kim KA, Shon JH, Park JY et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther. 2002; 72: 90-99.
22. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008; 84: 236-242.
23. Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 2008; 64: 589-597.
24. Kim SD, Kang W, Lee HW et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, openlabel, crossover study in healthy Korean male subjects. Clin Ther. 2009; 31: 793-803.
25. Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittel-Forschung. 2004; 54: 600-604. (Pubitemid 39278902)
26. Lau WC, Gurbel PA, Watkins PB et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109: 166-171.
27. Midha KK, Rawson MJ, Hubbard JW. Prescribability and switchability of highly variable drugs and drug products. J Control Release. 1999; 62: 33-40.
28. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89: 783-787. (Pubitemid 36603418)
29. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43: 1266-1274.
30. Park JY, Kim KA, Lee GS et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther. 2004; 26: 715-723.
31. Park JY, Kim KA, Park PW et al. Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Int J Clin Pharmacol Ther. 2006; 44: 641-647.
32. Park JY, Kim KA, Park PW et al. Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Clin Ther. 2006; 28: 1837-1847.
33. Pereillo JM, Maftouh M, Andrieu A et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002; 30: 1288-1295. (Pubitemid 35265838)
34. Rao TRK, Usha PR, Naidu MUR, Gogtay JA, Meena M. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res. 2003; 64: 685-696. (Pubitemid 38130684)
35. Rouhi A. Generic tide is rising. Chem Engineering News. 2002; 80: 37-51.
36. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2y(12), a new platelet ADPreceptor, target of clopidogrel. Biochem Biophys Res Commun. 2001; 283: 379-383.
37. Schroeder WS, Ghobrial L, Gandhi PJ. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J Thromb Thrombolysis. 2006; 22: 139-150. (Pubitemid 44473565)
38. Schuirmann DJ. Acomparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
39. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Annals of internal medicine. 1998; 129: 394-405.
40. Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Shekarchi M, Dalvandi A. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2006; 20: 1309-1314. (Pubitemid 46099737)
41. Tothfalusi L, Endrenyi L, Midha KK. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max). Int J Clin Pharmacol Ther. 2003; 41: 217-225. (Pubitemid 36603765)
42. Tucker GT. Chiral switches. Lancet. 2000; 355: 1085-1087.